Catalyst
Slingshot members are tracking this event:
SPIRIVA RESPIMAT Now Available in the U.S. for Maintenance Treatment of Asthma in Adults and Adolescents
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| Boehringer Ingelheim | Community voting in process | |||||
Additional Information
The FDA approved SPIRIVA RESPIMAT for the treatment of asthma based on efficacy and safety data from a comprehensive clinical trial program, including 12 trials of approximately 5,000 adults and adolescents with mild, moderate and severe symptomatic asthma on at least an inhaled corticosteroid (ICS).
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 04, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Spiriva Respimat, Market Release, Asthma
